Boston Scientific Corporation EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD 4.09 B

Boston Scientific Corporation EBITDA is USD 4.09 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 12.45% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Boston Scientific Corporation EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 3.64 B, a 28.28% change year over year.
  • Boston Scientific Corporation EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 2.84 B, a 10.61% change year over year.
  • Boston Scientific Corporation EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 2.56 B, a 58.76% change year over year.
  • Boston Scientific Corporation EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 1.61 B, a 5.90% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)